Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Enveric Biosciences (NASDAQ: ENVB) announced participation in various investor and industry conferences in June 2021, following its May 24 announcement of acquiring MagicMed Industries. Key speakers include David Johnson and Dr. Joseph Tucker, who will present at conferences such as the Benzinga Capital Conference, LD Micro Invitational XI, and H. C. Wainwright Conference. These events aim to showcase their innovative approaches to developing naturally occurring medicines to enhance the quality of life for cancer patients.
Enveric Biosciences (NASDAQ: ENVB) announced its definitive agreement to acquire MagicMed Industries, enhancing its portfolio with psychedelic-derived molecules for cancer and CNS therapies. The all-stock transaction involves approximately 9.9 million shares issued to MagicMed shareholders and is expected to close in the second half of 2021. Dr. Joseph Tucker, MagicMed’s CEO, will become Enveric’s CEO post-acquisition. Enveric aims to address cancer-related PTSD, leveraging MagicMed’s research capabilities and novel drug candidates. Additionally, Enveric will receive approximately $4 million CAD from MagicMed's treasury.
Enveric Biosciences (NASDAQ: ENVB) reported its financial results for Q1 2021, highlighting a net loss of $3.25 million and a significant increase in operating expenses to $6.76 million, up from $0.84 million in Q1 2020. The company raised $24.88 million through financing activities, primarily from the sale of common stock. With approximately $23 million in cash as of March 31, 2021, Enveric is positioned to initiate two critical Phase I/II trials for Glioblastoma Multiforme and Radiation Dermatitis later this year. Management changes include the appointment of a new CFO and enhancements to the Scientific Advisory Board.
Enveric Biosciences (ENVB) has appointed Dr. Arash Asher, Director of Cancer Rehabilitation at Cedars-Sinai, to its Scientific Advisory Board. Dr. Asher's expertise in managing chemotherapy-related side effects is expected to enhance the development of cannabinoid therapies aimed at improving cancer patients' quality of life. This appointment follows the board's first meeting on April 25, 2021, where they discussed clinical development plans for radiodermatitis and glioblastoma, emphasizing support for ongoing cannabinoid research.
Enveric Biosciences (NASDAQ:ENVB) announced that CEO David Johnson will present at the Planet MicroCap Showcase on April 21, 2021, at 9:00 a.m. ET. This virtual event aims to highlight the company's innovative cannabinoid medicines designed for cancer patients, particularly addressing issues like radiodermatitis and chemotherapy-induced neuropathy. Interested participants can register for the live presentation and access additional conference details through provided links. The company's commitment to patient-first solutions is emphasized throughout the announcement.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on cannabinoid medicines for cancer patients, announced the appointment of Carter Ward as Chief Financial Officer effective May 15, 2021. He replaces John Van Buiten, who will continue in a consulting role. Mr. Ward brings over 30 years of experience in life sciences and capital markets. His prior role was CFO at Elite Pharmaceuticals, where he led successful capital raises and financial initiatives. Enveric has made strategic progress since going public in late December 2020.
Enveric Biosciences (NASDAQ: ENVB) reported its financial results for the year ending December 31, 2020, alongside updates on its 2021 progress. The company secured approximately $22.8 million in gross proceeds through two direct offerings, enabling accelerated research on cannabinoid therapies for cancer patients. Enveric acquired exclusive licenses for five molecules targeting pain and dermatology and entered a collaboration with PureForm. They aim to initiate pivotal clinical trials in supportive care markets, including glioblastoma and radiation dermatitis, in 2021.
Enveric Biosciences (NASDAQ: ENVB) announced the appointment of Dr. Douglas D. Lind to its board of directors on March 18, 2021. Dr. Lind brings over 30 years of experience in healthcare and finance, having worked as a physician and a senior equity research analyst. He co-founded Biomark Capital, focusing on ventures in oncology and medical imaging. CEO Dave Johnson expressed confidence that Dr. Lind's diverse background will contribute significantly to enhancing treatment options for cancer patients, especially in managing side effects from therapies.
Enveric Biosciences (NASDAQ:ENVB), a biotechnology firm focused on cannabinoid medicines for cancer patients, discussed its recent acquisition of an exclusive license from Diverse Biotech in a video interview with CEO David Johnson. This strategic move aims to develop new treatments for conditions like radiodermatitis and chemotherapy-induced neuropathy. Enveric is dedicated to improving patient quality of life through rigorously tested innovations. The company continues to highlight its commitment to the cancer patient community through these advancements.
Diverse Biotech has finalized a strategic transaction with Enveric Biosciences, granting exclusive global rights to develop and commercialize five novel compounds targeting adverse side effects from cancer treatments. The deal includes an undisclosed upfront payment and future royalties on sales. Diverse Biotech utilizes a sophisticated drug discovery platform, leveraging cannabinoids to create new drug candidates that may offer enhanced efficacy and reduced side effects compared to current therapies. This collaboration aims to expedite the availability of these treatments for oncology patients.